Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y

被引:87
作者
Vezzani, A
Michalkiewicz, M
Michalkiewicz, T
Moneta, D
Ravizza, T
Richichi, C
Aliprandi, M
Mulé, F
Pirona, L
Gobbi, M
Schwarzer, C
Sperk, G
机构
[1] Ist Ric Farmacol Mario Negri, Dept Neurosci, Lab Expt Neurol, I-20157 Milan, Italy
[2] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA
[3] Univ Innsbruck, Dept Pharmacol, A-6020 Innsbruck, Austria
关键词
anticonvulsant; epilepsy; hippocampus; limbic; system; kainic acid; kindling;
D O I
10.1016/S0306-4522(01)00581-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Functional studies in epileptic tissue indicate that neuropeptide Y and some of its peptide analogs potently inhibit seizure activity. We investigated seizure susceptibility in transgenic rats overexpressing the rat neuropeptide Y gene under the control of its natural promoter. Seizures were induced in adult transgenic male rats and their wild-type littermates by i.c.v. injection of 0.3 mug kainic acid or by electrical kindling of the dorsal hippocampus. Transgenic rats showed a significant reduction in the number and duration of electroencephalographic seizures induced by kainate by 30% and 55% respectively (P < 0.05 and 0.01). Transgenic rats were also less susceptible to epileptogenesis than wild-type littermates as demonstrated by a 65% increase in the number of electrical stimuli required to induce stage 5 seizures (P < 0.01). This phenotype was associated with a strong and specific expression of neuropeptide Y mRNA in area CA1, a brain area involved in the seizure network. We conclude that endogenous neuropeptide Y overexpression in the rat hippocampus is associated with inhibition of seizures and epileptogenesis suggesting that this system may be a valuable target for developing novel antiepileptic treatments. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:237 / 243
页数:7
相关论文
共 43 条
[1]  
Amaral D.G., 1995, HIPPOCAMPAL FORMATIO, P443
[2]   Knock-out mice reveal a critical antiepileptic role for neuropeptide Y [J].
Baraban, SC ;
Hollopeter, G ;
Erickson, JC ;
Schwartzkroin, PA ;
Palmiter, RD .
JOURNAL OF NEUROSCIENCE, 1997, 17 (23) :8927-8936
[3]   REGULATION OF THE RELEASE OF COEXISTING NEUROTRANSMITTERS [J].
BARTFAI, T ;
IVERFELDT, K ;
FISONE, G ;
SERFOZO, P .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1988, 28 :285-310
[4]   INVESTIGATIONS INTO NEUROPEPTIDE Y-MEDIATED PRESYNAPTIC INHIBITION IN CULTURED HIPPOCAMPAL-NEURONS OF THE RAT [J].
BLEAKMAN, D ;
HARRISON, NL ;
COLMERS, WF ;
MILLER, RJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 (02) :334-340
[5]   Decreased levels of neuropeptide Y5 receptor binding sites in two experimental models of epilepsy [J].
Bregola, G ;
Dumont, Y ;
Fournier, A ;
Zucchini, S ;
Quirion, R ;
Simonato, M .
NEUROSCIENCE, 2000, 98 (04) :697-703
[6]   EFFECTS OF NEUROPEPTIDE-Y ON THE ELECTRICAL-PROPERTIES OF NEURONS [J].
COLMERS, WF ;
BLEAKMAN, D .
TRENDS IN NEUROSCIENCES, 1994, 17 (09) :373-379
[7]  
DEPRATO PS, 2000, NEUROSCI LETT, V287, P61
[8]  
DUMONT Y, 1995, J PHARMACOL EXP THER, V272, P673
[9]   Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y [J].
Erickson, JC ;
Clegg, KE ;
Palmiter, RD .
NATURE, 1996, 381 (6581) :415-418
[10]   Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy [J].
Furtinger, S ;
Pirker, S ;
Czech, T ;
Baumgartner, C ;
Ransmayr, G ;
Sperk, G .
JOURNAL OF NEUROSCIENCE, 2001, 21 (15) :5804-5812